A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study of VX-809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygous for the DeltaF508-CFTR Gene Mutation
|Effective start/end date||6/16/09 → 5/31/11|
- Vertex Pharmaceuticals Incorporated
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.